# HER2

Source: https://nuclide.cc/targets/her2/  
Nuclide record `her2` (Target). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

A growth-signal receptor. Some cancers make far too much of it, and drugs that block it or use it as a docking site have transformed those cancers.

## Summary

Human epidermal growth factor receptor 2 is a receptor tyrosine kinase amplified in ~15-20% of breast cancers and a subset of gastric, colorectal, lung (mutations), and biliary cancers. Trastuzumab (1998) was the first targeted antibody in solid tumours. Trastuzumab deruxtecan redefined the target by working in 'HER2-low' tumours that older drugs ignored, and in 2026 gained approval in early-stage disease.

## Fields

- Kind: Target
- Last checked: 2026-09-04
- Tags: adc-target; driver
- Symbol: ERBB2
- Class: surface-antigen
- Biology: Ligand-less receptor that heterodimerises with HER3/EGFR to drive PI3K and MAPK signalling. Amplification is a true oncogenic driver; low expression is merely a delivery address for ADCs.
- Where found: HER2+ breast cancer (~15-20%); HER2-low breast cancer (~50%); Gastric/GEJ (~15-20%); HER2-mutant NSCLC (~2-3%); Colorectal (~3-5%); Biliary tract

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/HER2/neu
- Wikipedia: https://en.wikipedia.org/wiki/HER2/neu

## Connected records

- indications: [Gastric and gastro-oesophageal junction adenocarcinoma](https://nuclide.cc/indications/gastric-oesophageal-cancer/), [HER2-positive breast cancer](https://nuclide.cc/indications/breast-her2-positive/), [Osteosarcoma](https://nuclide.cc/indications/osteosarcoma/)
- companies: [Precirix](https://nuclide.cc/companies/precirix/)
- trials: [HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011](https://nuclide.cc/trials/nct06369831/)
- technologies: [HER2 PET](https://nuclide.cc/technologies/her2-pet/), [Immuno-PET](https://nuclide.cc/technologies/immuno-pet/), [Radio-antibody & radio-ADC](https://nuclide.cc/technologies/radioimmunotherapy/)
- institutions: [UCLA Jonsson Comprehensive Cancer Center](https://nuclide.cc/institutions/ucla-jonsson/)
- terms: [Antigen](https://nuclide.cc/terms/antigen/)
- ideas: [Alpha radioligands after ADC failure](https://nuclide.cc/ideas/idea-alpha-after-adc/), [Pretargeted alpha radioimmunotherapy](https://nuclide.cc/ideas/idea-pretargeted-alpha-therapy/)
- people: [Jason S. Lewis](https://nuclide.cc/people/jason-lewis/)
- isotopes: [Thorium-227](https://nuclide.cc/isotopes/th-227/)
- targets: [Claudin-18.2](https://nuclide.cc/targets/cldn18-2/), [HER3 (ERBB3)](https://nuclide.cc/targets/her3/)

---
JSON: https://nuclide.cc/api/v1/entities/her2.json